Sandoz has now taken the final step in its long journey of separation from Novartis, becoming a standalone firm as it completed its spinoff from the former parent company. But as that process comes to an end, another journey is just beginning for Sandoz, as it sets out on its own as an independent global generics and biosimilars industry leader.
Key Takeaways:
-
Sandoz is now a standalone company, having formally been spun off from Novartis
-
Today, October 4, is the first trading day for Sandoz on the SIX Swiss Exchange
-
Some links between the two firms will remain,
The firm heralded a “new era as a standalone global leader and European champion in generic and biosimilar medicines” as it confirmed that the spinoff had now taken
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?